Earnings Releases·Nov 13, 2026, 8:00 AM ET

Immunic, Inc. — Third Quarter 2026 Earnings Summary

**Financial Results:** Operating expenses rose to $43.4 million for Q3 2026 (vs. $26.0 million in Q3 2025), driven by G&A increases to $19.4 million; net loss widened to $42.3 million ($0.99/share) from $25.6 million ($1.32/share) in the prior year period.
**Balance Sheet & Liquidity:** Cash and cash equivalents surged to $132.0 million as of September 30, 2026, following a February 2026 private placement, compared to $15.5 million at year-end 2025, providing funding runway into late 2027.
**Clinical Outlook:** Top-line data from Phase 3 ENSURE-1 and ENSURE-2 trials in relapsing MS is expected in December 2026, with a potential NDA submission targeted for mid-2027 and regulatory approval in 2028 if results are positive.
**Strategic Developments:** Management is transitioning to a commercial organization, evidenced by the appointment of a Chief People Officer and Chief Data and Digital Officer, alongside the ongoing initiation of the Phase 3 PROTECT-MS trial in progressive MS.